Choosing the therapy for neurological infection with rapidly growing mycobacteria

Atman Dash¹, Nitin Gupta², Yogiraj Ray², Parul Kodan², Binit Kumar Singh², Manish Soneja²,*

¹ Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India; ² Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.

Summary The management of neurological infections due to non-tubercular mycobacteria is extremely challenging because of scarce literature, issues with penetration, lack of easily available susceptibility platforms and adverse effects associated with long term therapy. We report a case of a young girl with neurological infection due to rapidly growing mycobacteria to discuss the factors that should be considered while choosing the therapy for such rare and persistent infections.

Keywords non-tubercular mycobacteria, rapidly growing mycobacteria, carbapenems, aminoglycosides

Rapidly growing non-tubercular mycobacteria (NTM) are uncommonly associated with infections involving lungs, bones or soft tissues (1-4). They usually occur following trauma, contamination during surgery, hematogenous infection from a distant focus or contiguous spread from wounds or perforated gut (6-7). These organisms may very rarely involve the central nervous system (CNS) as well. The treatment of NTM is mostly based on small observational studies as there are no properly conducted clinical trials in this area. With the exception of a few case reports, there is hardly any literature on NTM involving the CNS. This, along with the issues of penetration, lack of easily available susceptibility platforms and adverse effects associated with long term therapy, makes the management extremely challenging. We discuss the factors that should be considered while choosing the therapy for such infections using a case of ventriculoperitoneal (VP) shunt infection with Mycobacterium fortuitum that we managed recently.

A 13-years old female patient, a known case of posterior fossa glioma with bilateral ventriculoperitoneal shunt in-situ (for four years) presented to an outside hospital with acute appendicitis. She was found to have an inflamed appendix which was removed laparoscopically. Fifteen days after the surgery, she presented to our hospital with high-grade fever and altered sensorium with convulsions. She was found to have a Glasgow Coma Score of 9 (Eye-3, Verbal-2, Motor-4). A large, firm and mobile swelling was noticed on the abdominal examination. Computerized tomography (CT) scan of the brain showed dilated ventricles, and CT abdomen showed a large uniloculated cyst (pseudocyst) enclosing the shunt tips. Cerebrospinal fluid examination (CSF) revealed a total leucocyte count of 280/μL (neutrophil 70%, lymphocyte 30%), a glucose of 80 mg/dl and a protein of 14 mg/dl. Ziehl Neelsen staining of the CSF showed multiple acid-fast bacilli (3+) and the growth in culture was identified as Mycobacterium fortuitum by line probe assay and sequencing (Figure 1). The likely source of shunt infection in our case was the laparoscope used in the appendectomy. We hypothesized that the infection in the CSF was a result of ascending infection from the peritoneal end of the VP shunt. She was started on imipenem (intravenous), amikacin (intravenous),

Figure 1. Ziehl Neelsen stain of cerebrospinal fluid showing acid-fast bacilli.
levofloxacin (oral) and linezolid (oral). All the shunt hard
wares were removed, and a frontal Ommaya reservoir
was inserted. The endoscopic third ventriculostomy was
done after the CSF became sterile. She was discharged
after two months with oral levofloxacin and linezolid.
The therapy was discontinued after one and a half year of
oral therapy.

Treatment in such cases requires appropriate
antimicrobials effective against the species of NTM
causing the infection. It is generally suggested to use at
least one or two parenteral drugs for the initial part of
therapy followed by a prolonged course of oral therapy
(5). We chose a regimen containing four drugs for the
initial part of the therapy considering the involvement
of CNS, the severity of the condition and lack of
susceptibility testing. The oral therapy with two drugs
was prolonged beyond one year for the same reason.
The choice was based on the percentage susceptibility,
penetration in CSF and adverse effect profile (8) (Table
1). Shunt hardware is a source for colonization of
the bacteria because of its inherent property to form
biofilms. Removal of all such shunt material is necessary
to achieve a good outcome, as noted in the literature.
CNS infection with NTM is a rare but potentially fatal
condition. Besides a high index of suspicion and early
diagnosis, choosing the right therapy for the correct
duration is paramount for a favourable outcome.

References

1. Wallace Jr RJ, Musser JM, Hull SI, Silcox VA, Steele
LC, Forrester GD, Labidi A, Selandier RK. Diversity and
sources of rapidly growing mycobacteria associated with
infections following cardiac surgery. J Infect Dis. 1989;
159:708-716.
2. Clegg HW, Foster MT, Sanders WE, Baine WB. Infection
due to organisms of the Mycobacterium fortuitum
complex after augmentation mammoplasty: clinical and
Abscesses due to mycobacterium abscessus linked to
injection of unapproved alternative medication. Emerg
J, Gillies D, Vugia DJ. An outbreak of mycobacterial
furunculosis associated with footbaths at a nail salon. N
5. Talati NJ, Rouphael N, Kuppalli K, Franco-Paredes C.
Spectrum of CNS disease caused by rapidly growing
7. Kulkarni AV, Drake JM, Lamberti-Pasculli M.
Cerebrospinal fluid shunt infection: a prospective study
the blood-cerebrospinal fluid/blood-brain barrier for
treatment of central nervous system infections. Clin

Received May 4, 2020; Revised July 24, 2020; Accepted

*Address correspondence to:
Manish Soneja, Department of Medicine, Teaching Block,
All India Institute of Medical Sciences, Ansari Nagar, New
Delhi-110029, India.
E-mail: manishsoneja@gmail.com

Released online in J-STAGE as advance publication August

www.ddtjournal.com

<table>
<thead>
<tr>
<th>Drug</th>
<th>Percentage susceptibility</th>
<th>Dose and formulation</th>
<th>AUCCSF/AUCCS (uninflamed meninges)</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin</td>
<td>100</td>
<td>5 mg/kg/dose q8 h IV</td>
<td>0.2</td>
<td>Nephrotoxicity, Ototoxicity, neurotoxicity</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>100</td>
<td>500-750 mg q24h IV or oral</td>
<td>0.71</td>
<td>Gastrointestinal, headache, insomnia</td>
</tr>
<tr>
<td>Imipenem</td>
<td>100</td>
<td>500 mg q6 h IV</td>
<td>0.2</td>
<td>Anemia, thrombocytopenia, transaminitis</td>
</tr>
<tr>
<td>Linezolid</td>
<td>86</td>
<td>600 mg q12 h IV or oral</td>
<td>0.9</td>
<td>Diarrhea, leucopenia, thrombocytopenia</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>50</td>
<td>100 mg q12 h IV or oral</td>
<td>0.2</td>
<td>Diarrhea, nasopharyngitis</td>
</tr>
<tr>
<td>Minocycline</td>
<td>50</td>
<td>200 mg loading followed by 100 mg q12 h</td>
<td>No data</td>
<td>Dizziness, fatigue, pruritus</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>50</td>
<td>500 mg q12 h oral</td>
<td>No data</td>
<td>Dysgeusia, diarrhoea</td>
</tr>
</tbody>
</table>

*AUCCSF/AUCCS: Area under curve of drug in cerebrospinal fluid divided by area under curve in serum.